Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 1

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 1
---
 thereunto duly authorized.

| GENMAB A/S |     |                                                           |
| BY:        |     | /s/ Anthony Pagano                                        |
|            |     | Name: Anthony Pagano                                      |
|            |     | Title: Executive Vice President & Chief Financial Officer |

#### DATE: August 07, 2025

#### 99.1
Genmab Announces Financial Results for the First Half of 2025

#### August 7, 2025 Copenhagen, Denmark;
Interim Report for the First Half Ended June 30, 2025

#### Highlights
• Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R 2 in patients with relapsed or refractory FL

• Rinatabart sesutecan (Rina-S ® ) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data presented at the 2025 ASCO Annual Meeting

• Data from over 40 abstracts highlighting the depth, breadth and strength of Genmab’s comprehensive epcoritamab development program presented at multiple medical conferences

• Genmab revenue increased 19% compared to the first six months of 2024, to $1,640 million

“In the first half of the year we continued to make progress towards our strategic priorities as we strive towards our goal of bringing our innovative therapies to additional patients in need. We further maximized the potential of our commercialized medicines with an additional sBLA submission for EPKINLY ® (epcoritamab-bysp) and the launch of Tivdak ® (tisotumab vedotin) in Japan. We also accelerated the development of our late-stage pipeline through both encouraging data presentations and, for Rina-S, the announcement of additional planned Phase 3 clinical trials,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

#### Financial Performance First Half of 2025
• Revenue was $1,640 million for the first six months of 2025 compared to $1,382 million for the first six months of 2024. The increase of $258 million, or 19%, was primarily driven by higher DARZALEX ® and Kesimpta ® royalties achieved under our collaborations with Johnson & Johnson (J&J) and Novartis Pharma AG (Novartis), respectively, and higher EPK